Figure 1
Kaplan-Meier estimate of the probability of survival after transplantation for DBA. UCB 5 umbilical cord blood; BM 5 bone marrow. Cases in which post-transplant survival days were not described were omitted.
Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor therapy in an allogeneic blood stem cell donor
Of recent interest has been the use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) mobilized peripheral blood stem cells for allogeneic transplantation. 1 While rhG-CSF therapy in normal allogeneic donors has been generally well tolerated, an increasing list of acute complications has been described. We would like to add another acute complication of rhG-CSF in an allogeneic blood stem cell donor, namely acute gouty arthritis.
A 65-year-old male with a history of coronary artery disease was identified as an HLA-genotypically identical stem cell donor for his sister who had acute myeloid leukemia. The donor had a history of asthma, coronary artery disease with two previous angioplastic procedures (in November 1996), degenerative arthritis of the right knee (status post right knee replacement) and hypercholesterolemia. He took pravachol 20 mg daily and one aspirin daily. He had no history of gout. Physical examination prior to administration of rhG-CSF revealed no joint swelling, erythema tenderness or deformities. A baseline uric acid level was 8.2 mg/dl (normal range 3.6 to 8.5). rhG-CSF was begun at a dose of 10 mg/kg per day. On the second day of treatment he noticed tenderness on the back of his heel (in an area of previous Achilles tendon surgery). He saw his private physician who prescribed cephalexin for presumed cellulitis. Over the next several days erythema and tenderness over the heel area progressed. On the morning of intended stem cell donation (following 5 days of G-CSF therapy), examination of left foot was remarkable for marked erythema, warmth and tenderness with fluctuance over the left heel, swelling of the plantar surface of the foot, and erythema and edema of the distal left foot and left third toe. His peripheral white blood count was 33.9 × 10 9 /l. A repeat uric acid level was not obtained. A presumptive diagnosis of cellulitis was made and broad spectrum antibacterial antibiotics were begun (nafcillin and ofloxacin). A subsequent needle aspiration of the left heel area however revealed urate crystals. Treatment with colchicine resulted in prompt improvement of symptoms and signs of his arthritis.
This stem cell donor may have been predisposed to gouty arthritis by virtue of having a high normal uric acid level and by taking aspirin. However a rapid rhG-CSF expansion (and turnover) of his myeloid pool probably led to precipitation of acute gouty arthritis and tendonitis.
As discussed in a recent review by Anderlini et al, 1 rhG-CSF therapy is generally well tolerated in normal stem cell donors with only an approximately 1-3% incidence of rhG-CSF discontinuation having been observed. There are, however, anecdotal reports of acute complications following rhG-CSF therapy of normal donors ranging from inflammatory conditions (eg acute iritis), 2 temporally related thrombotic events (cerebrovascular accident, myocardial infarction) 1 and more recently spontaneous splenic rupture.
harvest) have already been described. In view of increasing adoption by many transplant centers of this practice, support for a formal blood stem cell donor registry is urged so that long-term donor safety can be ensured.
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